Skip to main content
Premium Trial:

Request an Annual Quote

Eric Fung, Simon Shorter, Bjrn Ekstrm, John Murphy, Robert Friel, John Roush, Douglas Obenshain, Mor Amitai

Premium

Eric Fung has been promoted within Ciphergen’s diagnostic division to vice president of clinical and medical affairs. In his new position, Fung will manage biomarker discovery efforts within academic collaborations and direct clinical trial studies designed to achieve commercialization, the company said.

Ciphergen has also appointed Simon Shorter as vice president of business development. In his position, Shorter will oversee corporate strategy and academic business development activities, the company said.


Björn Ekström has become CEO of Olink Bioscience, a Swedish company founded in September that focuses on protein analysis technology. Previously, he was EVP and head of R&D at Pyrosequencing. He also held several positions within R&D at Amersham Biosciences and Pharmacia Biotech.


Perkin Elmer announced this week that it has named John Murphy executive vice president and chief operating officer. In this newly-created position, Murphy will oversee activities in improving operational efficiencies with particular emphasis on the supply chain. In addition, he will oversee the company’s strategy to expand medical imaging applications across health sciences markets and lead the company’s China growth strategy.

In addition, Perkin Elmer appointed Robert Friel as executive vice president and chief financial officer for business development, and John Roush as president of the company’s optoelectronics business. Friel had served as chief financial officer since 1999, and will now also direct the company’s business development activities, focusing on strategic growth opportunities in health sciences and select advanced technologies. Roush had previously served as general manager of two business units within the Optoelectronics division.


The Burnham Institute last week announced that Douglas Obenshain has been elected to its board of trustees. Obenshain is a partner with Ernst & Young, where his practice focuses primarily on biotechnology, pharmaceutical, and medical device companies, the institute said.


Mor Amitai will step down as president and CEO of Compugen by the end of 2005, the Tel Aviv-based company said last week. Compugen is now searching for a new CEO with more experience in pharmaceutical product development and commercialization.

 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.